Actio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.
Jazz acquires Actio for $1.3B to add ABS-1230, first KCNT1-epilepsy drug for 2,500 U.S. patients; showed meaningful seizure reductions in trials. This reflects biotech M&A acceleration: 19 deals in H1 2026 exceed five-year annual totals, consolidating rare-disease leadership.
An article from
Dive Brief
Actio Biosciences, which will receive $820 million up front in the deal, adds to a major upswing in private biotech buyouts seen throughout this year.
Published Aug. 10, 2026
Jazz Pharmaceuticals displays a corporate sign at the ASCO annual meeting in Chicago on June 2, 2018.
Jazz Pharmaceuticals will buy Actio Biosciences for $820 million upfront and up to $500 million more if certain milestones are…
Jazz Pharmaceuticals will acquire Actio Biosciences, Inc., a deal that expands Jazz's pipeline and presence in rare epilepsy…
Jazz Pharmaceuticals teams with AbCellera on cancer therapies as analysts maintain positive targets despite a recent Zepzelca…
The potentially $4 billion collaboration is the latest example of drugmakers working to broaden the use of T cell engagers,…
Jazz Pharmaceuticals (JAZZ) reported Q2 sales above estimates and raised its FY26 sales guidance. Analysts have mixed opinions,…
Bernstein initiated coverage of Jazz Pharmaceuticals (JAZZ) with a Market Perform rating and $229 price target The firm believes…
